世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

創薬サービス市場：プロセス（ターゲット選定、バリデーション、ヒット・トゥ・リード）、タイプ（化学、生物学）、薬剤タイプ（低分子、生物学）、治療領域（腫瘍、神経）、エンドユーザー（製薬、バイオテック）別 - 2026年までの世界予測


Drug Discovery Services Market by Process (Target Selection, Validation, Hit-to-lead), Type (Chemistry, Biology), Drug Type (Small molecules, biologics), Therapeutic Area (Oncology, Neurology) End User (Pharma, Biotech) - Global Forecast to 2026

創薬サービスの世界市場は、2021年の161億米ドルから2026年には314億米ドルに達すると予測され、2021年から2026年の予測期間中に14.3%のCAGRで推移するとされています。製薬・バイオ医薬品業界における研究開発費... もっと見る

　

　

出版社 出版年月 電子版価格 ページ数 図表数 言語
MarketsandMarkets
マーケッツアンドマーケッツ 		2022年2月2日 US$4,950
シングルユーザライセンス
ライセンス・価格情報
注文方法はこちら 		282 303 英語

日本語のページは自動翻訳を利用し作成しています。


　

サマリー

創薬サービスの世界市場は、2021年の161億米ドルから2026年には314億米ドルに達すると予測され、2021年から2026年の予測期間中に14.3%のCAGRで推移するとされています。製薬・バイオ医薬品業界における研究開発費の増加、分析試験サービスのアウトソーシング需要の増加、希少疾患やオーファンドラッグの研究への取り組み、自社での医薬品開発コストの高さが、創薬サービス市場に新しい収益ポケットを作り出しています。

"2020年の創薬サービス市場におけるタイプ別セグメントでは、ケミストリーサービスが最大のシェアを占めている"
創薬サービス市場は、タイプ別に、ケミストリーサービスとバイオロジーサービスに分類されます。2020年の同市場では、ケミストリーサービスが最大のシェアを占めた。この市場セグメントの成長は、堅牢な候補を提供するために、さまざまな初期の医薬品開発段階で化学を広く適用していることが主な理由です。また、学術機関、バイオテクノロジー企業、大手製薬会社で化学が広く利用されていることも、市場の成長を支えています。
"2020年の創薬サービス市場において、ヒット・トゥ・リード識別セグメントがプロセスセグメントで最大のシェアを占める"
創薬サービス市場は、プロセスによって、ターゲット選択、ターゲットバリデーション、ヒット・トゥ・リード同定、リード最適化、候補者バリデーションに大別されます。2020年の創薬サービス市場では、Hit-to-Lead同定分野が最大のシェアを占めています。創薬における重要な役割のため、hit-to-lead identificationは最も収益性の高いプロセスであり、現在、多くのCROがこれらのサービスを製薬会社に提供している。
"2020年の創薬サービス市場において、治療分野別ではオンコロジー分野が最大のシェアを占めている"
創薬サービス市場は、治療領域別に、がん、感染症・免疫系疾患、神経、消化器系疾患、循環器系疾患、その他の治療領域に区分されます。がん領域は、がんの発生率が高いこと、がん治療薬の研究数が増加していること、企業が革新的ながん治療薬の市場投入に注力していることから、この市場の最大セグメントとなっています。

ラボラトリー・コーポレーション・オブ・アメリカ・ホールディングス（米国）、ユーロフィンズ・サイエンティフィックSE（ドイツ）、チャールズ・リバー・ラボラトリーズ・インターナショナル, Inc.（米国）。(米国）、Evotec SE（ドイツ）、WuXi AppTec（中国）、Pharmaceutical Product Development LLC（米国）、Syngene International Limited（インド）、キュリア グローバル インク（米国）、Syngene International Limited（インド）、Syngene International Limited（インド）、Curia Global Inc.(米国)、Dr. Reddy Laboratories Ltd. (米国)。(Aurigene Discovery Technologies)（インド）、Pharmaron Beijing Co.(中国)、Piramal Enterprises Limited (インド)、Thermo Fisher Scientific Inc.(米国)などが創薬サービス市場で事業を展開している主要企業です。

"アジア太平洋地域創薬サービス市場において最も成長率の高い地域"
創薬サービス市場は、北米、欧州、アジア太平洋地域、中南米（LATAM）、中東・アフリカ（MEA）に区分されます。APACは予測期間中、最も高いCAGRを記録すると推定されています。膨大な患者数、新興の中間層、政府支出の増加、治療分野の専門知識などが、この地域の医薬品産業の主な成長要因となっています。世界の製薬会社は、その繁栄する市場に参入するため、またアジアに製造拠点を移すことで製造コストを削減するために、ますますアジアへの進出を進めています。

本レポートのために実施した一次インタビューは、以下のように分類される。

- 回答者別供給側70％、需要側30
- 職位別管理職-55%、CXOおよびディレクタークラス-30%、経営幹部-25
- 地域別北米 -20%、欧州 -10%、アジア太平洋 -55%、RoW-15%。
報告書に掲載された企業一覧
- ラボラトリー・コーポレーション・オブ・アメリカ・ホールディングス (アメリカ)
- ユーロフィンズサイエンティフィックSE（ドイツ）
- チャールズ・リバー・ラボラトリーズ・インターナショナル、Inc.(アメリカ)
- エボテックSE（ドイツ）
- WuXi AppTec (中国)
- ファーマシューティカル・プロダクト・デベロプメント LLC（米国）
- シンジェン・インターナショナル・リミテッド（インド）
- キュリア グローバル インク(米国)
- ドクター・レディ・ラボラトリーズLtd.(Aurigene Discovery Technologies）（インド）
- ファーマロン北京有限公司(中国)
- ピラマル・エンタープライズ・リミテッド（インド）
- サーモフィッシャーサイエンティフィック社(米国)
- Jubilant Pharmova Limited（インド）
- GenScript Biotech Corporation（米国）
- セルビタ社（ポーランド）
- 上海メディシロン社(中国)
- ビババイオテック(上海)有限公司(中国)
- TCGライフサイエンス社(インド)
- 上海ケムパートナー有限公司（Shanghai ChemPartner Co.(中国)
- ドメインエックス・リミテッド(イギリス)
- NUVISAN Pharma Holding GmbH（ドイツ）
- フロンテッジ・ホールディングス・コーポレーション（米国）
- ダルトンファーマサービス（カナダ）
- アラゲンライフサイエンス社(インド)
- プロメガ・コーポレーション（米国）
調査範囲
本レポートは、創薬市場の詳細なイメージを提供します。製品、用途、エンドユーザー、地域など、さまざまなセグメントにおける市場規模と今後の成長性を推定することを目的としています。また、主要な市場プレイヤーの企業プロファイルや最近の開発状況、主要な市場戦略とともに、詳細な競合分析も掲載しています。

レポート購入の主なメリット
本レポートは、創薬市場全体とそのサブセグメントに関する収益数の最も近い概算を提供することにより、市場リーダー/新規参入者を支援します。また、利害関係者が競合状況をよりよく理解し、自社のビジネスをよりよく位置づけ、適切な市場参入戦略を立てるためのより多くの洞察を得るのに役立ちます。本レポートは、利害関係者が市場の脈動を理解し、主要な市場促進要因、阻害要因、課題、トレンド、機会に関する情報を提供することを可能にします。

　

ページTOPに戻る


　

Summary

The global Drug discovery services market is projected to reach USD 31.4 billion by 2026 from USD 16.1 billion in 2021, at a CAGR of 14.3% during the forecast period of 2021 to 2026. Growing R&D expenditure in the pharmaceutical & biopharmaceutical industry, increasing demand for outsourcing analytical testing services, initiatives for research on rare diseases and orphan drugs, and the high cost of in-house drug development are creating new revenue pockets in the drug discovery services market.

“The chemistry services segment accounted for the largest share of the type segment in the drug discovery services market in 2020”
Based on type, the drug discovery services market is segmented into chemistry and biology services. The chemistry services segment commanded the largest share of this market in 2020. Growth in this market segment is largely due to the widespread application of chemistry in various early drug development phases to deliver robust candidates. The extensive usage of chemistry in academics, biotechnology companies, and large pharmaceutical companies also supports market growth.
“The Hit-to-lead identification segment accounted for the largest share of the process segment in the drug discovery services market in 2020”
Based on process, the drug discovery services market is broadly classified into target selection, target validation, hit-to-lead identification, lead optimization, and candidate validation. Hit-to-lead identification segment accounted for the largest share of the drug discovery services market in 2020. Due to its vital role in drug discovery, hit-to-lead identification is the most revenue-generating process, and currently, many CROs are offering these services to pharmaceutical companies.
“The Oncology segment accounted for the largest share of the therapeutic area segment in the drug discovery services market in 2020”
Based on therapeutic area, the drug discovery services market is segmented into oncology, infectious and immune system diseases, neurology, digestive system diseases, cardiovascular diseases, and other therapeutic areas. Oncology is the largest segment in this market owing to the high incidence of cancer, a growing number of research studies on cancer therapeutics, and a company focus on bringing innovative cancer drugs into the market.

Laboratory Corporation of America Holdings (US), Eurofins Scientific SE (Germany), Charles River Laboratories International, Inc. (US), Evotec SE (Germany), WuXi AppTec (China), Pharmaceutical Product Development LLC (US), Syngene International Limited (India), Curia Global Inc. (US), Dr. Reddy Laboratories Ltd. (Aurigene Discovery Technologies) (India), Pharmaron Beijing Co., Ltd. (China), Piramal Enterprises Limited (India), Thermo Fisher Scientific Inc. (US) are some of the major players operating in the drug discovery services market.

“Asia Pacific: The fastest-growing region in the drug discovery services market”
The drug discovery services market is segmented into North America, Europe, Asia Pacific, Latin America (LATAM) and Middle East and Africa (MEA). The APAC is estimated to record the highest CAGR during the forecast period. The vast patient population, emerging middle-class, rising government spending, and therapeutic area expertise are the major growth drivers for the pharmaceutical industry in the region. Global pharmaceutical firms are increasingly moving to Asia to tap into its thriving market and lower their production costs by shifting manufacturing to the region.

The primary interviews conducted for this report can be categorized as follows:

• By Respondent: Supply Side- 70% and Demand Side 30%
• By Designation: Managers- 55%, CXOs and Director level - 30%, and Executives - 25%
• By Region: North America -20%, Europe -10%, Asia-Pacific -55%, RoW -15%
List of Companies Profiled in the Report:
• Laboratory Corporation of America Holdings (US)
• Eurofins Scientific SE (Germany)
• Charles River Laboratories International, Inc. (US)
• Evotec SE (Germany)
• WuXi AppTec (China)
• Pharmaceutical Product Development LLC (US)
• Syngene International Limited (India)
• Curia Global Inc. (US)
• Dr. Reddy Laboratories Ltd. (Aurigene Discovery Technologies) (India)
• Pharmaron Beijing Co., Ltd. (China)
• Piramal Enterprises Limited (India)
• Thermo Fisher Scientific Inc. (US)
• Jubilant Pharmova Limited (India)
• GenScript Biotech Corporation (US)
• Selvita S.A. (Poland)
• Shanghai Medicilon Inc. (China)
• Viva Biotech (Shanghai) Ltd. (China)
• TCG Lifesciences Pvt Ltd. (India)
• Shanghai ChemPartner Co., Ltd. (China)
• Domainex Ltd. (UK)
• NUVISAN Pharma Holding GmbH (Germany)
• Frontage Holdings Corporation (US)
• Dalton Pharma Services (Canada)
• Aragen Life Sciences Pvt. Ltd. (India)
• Promega Corporation (US)
Research Coverage:
This report provides a detailed picture of the drug discovery market. It aims at estimating the size and future growth potential of the market across different segments such as the product, application, end user and region. The report also includes an in-depth competitive analysis of the key market players along with their company profiles recent developments and key market strategies.

Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall drug discovery market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, challenges, trends, and opportunities.



ページTOPに戻る


Table of Contents

1 INTRODUCTION 37
1.1 OBJECTIVES OF THE STUDY 37
1.2 MARKET DEFINITION 37
1.2.1 INCLUSIONS & EXCLUSIONS OF THE STUDY 37
1.3 MARKET SCOPE 38
1.3.1 MARKETS COVERED 38
1.3.2 YEARS CONSIDERED FOR THE STUDY 38
1.4 CURRENCY 39
1.5 LIMITATIONS 39
1.6 STAKEHOLDERS 39
1.7 SUMMARY OF CHANGES 40
2 RESEARCH METHODOLOGY 41
2.1 RESEARCH DATA 41
FIGURE 1 RESEARCH DESIGN 41
2.1.1 SECONDARY DATA 42
2.1.2 PRIMARY DATA 42
FIGURE 2 DRUG DISCOVERY SERVICES MARKET: BREAKDOWN OF PRIMARIES 43
2.2 MARKET ESTIMATION METHODOLOGY 44
FIGURE 3 DRUG DISCOVERY SERVICES MARKET SIZE ESTIMATION 
(SUPPLY-SIDE ANALYSIS), 2020 44
FIGURE 4 MARKET SIZE ESTIMATION: APPROACH 1 
(COMPANY REVENUE ANALYSIS-BASED ESTIMATION), 2020 45
FIGURE 5 ILLUSTRATIVE EXAMPLE OF COMPANY REVENUE ANALYSIS, 2020 46
2.2.1 INSIGHTS FROM PRIMARY EXPERTS 47
FIGURE 6 MARKET SIZE VALIDATION FROM PRIMARY SOURCES 47
2.3 MARKET GROWTH RATE PROJECTIONS 48
FIGURE 7 DRUG DISCOVERY SERVICES MARKET (SUPPLY-SIDE): CAGR PROJECTIONS 49
FIGURE 8 DRUG DISCOVERY SERVICES MARKET (DEMAND-SIDE): GROWTH ANALYSIS OF DEMAND-SIDE DRIVERS 49
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION 50
FIGURE 9 DATA TRIANGULATION METHODOLOGY 50
2.5 RESEARCH ASSUMPTIONS 51
2.6 COVID-19 SPECIFIC ASSUMPTIONS 51
2.7 RISK ANALYSIS 52
 
3 EXECUTIVE SUMMARY 53
FIGURE 10 DRUG DISCOVERY SERVICES MARKET, BY TYPE, 
2021 VS. 2026 (USD MILLION) 53
FIGURE 11 DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 
2021 VS. 2026 (USD MILLION) 54
FIGURE 12 DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 
2021 VS. 2026 (USD MILLION) 54
FIGURE 13 DRUG DISCOVERY SERVICES MARKET, BY END USER, 
2021 VS. 2026 (USD MILLION) 55
FIGURE 14 GEOGRAPHICAL SNAPSHOT OF THE DRUG DISCOVERY SERVICES MARKET 56
4 PREMIUM INSIGHTS 57
4.1 DRUG DISCOVERY SERVICES MARKET OVERVIEW 57
FIGURE 15 INCREASING R&D EXPENDITURE IN THE PHARMACEUTICAL AND BIOPHARMACEUTICAL INDUSTRY WILL DRIVE MARKET GROWTH 57
4.2 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE AND COUNTRY (2020) 58
FIGURE 16 SMALL-MOLECULE DRUGS ACCOUNTED FOR THE LARGEST SHARE 
OF THE NORTH AMERICAN DRUG DISCOVERY MARKET IN 2020 58
4.3 DRUG DISCOVERY SERVICES MARKET SHARE, BY TYPE (2020) 58
FIGURE 17 CHEMISTRY SERVICES SEGMENT ACCOUNTED FOR THE LARGEST MARKET SHARE IN 2020 58
4.4 DRUG DISCOVERY SERVICES MARKET, BY END USER, 2021 VS. 2026 (USD MILLION) 59
FIGURE 18 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES WILL CONTINUE TO DOMINATE THE MARKET IN 2026 59
4.5 DRUG DISCOVERY SERVICES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 60
FIGURE 19 ASIA PACIFIC COUNTRIES TO REGISTER THE HIGHEST GROWTH IN THE DRUG DISCOVERY SERVICES MARKET FROM 2021 TO 2026 60
5 MARKET OVERVIEW 61
5.1 INTRODUCTION 61
TABLE 1 DRUG DISCOVERY AND DEVELOPMENT PROCESS OVERVIEW 61
5.2 MARKET DYNAMICS 62
FIGURE 20 DRUG DISCOVERY SERVICES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 62
TABLE 2 DRUG DISCOVERY SERVICES MARKET: IMPACT ANALYSIS 62
5.2.1 DRIVERS 63
5.2.1.1 Growing R&D expenditure in the pharma & biopharma industry 63
FIGURE 21 RISING GLOBAL PHARMACEUTICAL R&D SPENDING, 2012–2026 63
5.2.1.2 Increasing demand for outsourcing analytical testing 64
FIGURE 22 ACTIVE PHARMACEUTICAL PIPELINE, 2011–2021 64
5.2.1.3 Initiatives for research on rare diseases and orphan drugs 64
FIGURE 23 NUMBER OF ORPHAN INDICATIONS APPROVED IN THE US (2010–2019) 65
5.2.1.4 High cost of in-house drug development 65
FIGURE 24 AVERAGE COST TO DEVELOP A PHARMACEUTICAL COMPOUND FROM DISCOVERY TO LAUNCH, 2010–2020 (USD BILLION) 66
5.2.2 RESTRAINTS 66
5.2.2.1 Stringent regulations governing drug discovery and animal usage 66
5.2.3 OPPORTUNITIES 67
5.2.3.1 Growth in drugs and biologics market despite COVID-19 pandemic 67
FIGURE 25 TOTAL NUMBER OF NEW DRUGS (NEW CHEMICAL ENTITIES AND BIOLOGICS) APPROVED BY US FDA (2001–2020) 67
TABLE 3 LIST OF BIOLOGICS APPROVALS BY US FDA, 2020 67
5.2.3.2 Rising demand for specialized testing services among end users 68
5.2.3.3 Patent expiry 69
TABLE 4 US: BIOLOGICS GOING OFF-PATENT DURING 2018–2025 69
5.2.3.4 High growth prospects in emerging markets 69
5.2.4 CHALLENGES 70
5.2.4.1 Shortage of skilled personnel 70
5.2.5 MARKET TRENDS 70
5.2.5.1 Shift in drug discovery services due to growing adoption of AI-based tools 70
5.2.5.2 Increased outsourcing to emerging Asian economies 71
5.2.5.3 CRO industry consolidation 72
TABLE 5 LIST OF ACQUISITIONS 72
5.2.5.4 Integrated end-to-end R&D service solution 73
5.3 IMPACT OF COVID-19 ON THE DRUG DISCOVERY SERVICES MARKET 73
FIGURE 26 DRUG DISCOVERY SERVICES MARKET SCENARIO WITH AND 
WITHOUT COVID-19 IMPACT, 2019–2026 74
5.3.1 ASSUMPTIONS – DRUG DISCOVERY SERVICES MARKET ESTIMATION AND FORECAST 74
5.3.2 ASSUMPTIONS – COMPANY REVENUE GROWTH 75
5.4 RANGES/SCENARIO 75
FIGURE 27 SPECTRUM OF SCENARIOS BASED ON THE IMPACT OF UNCERTAINTIES ON THE GROWTH OF THE DRUG DISCOVERY SERVICES MARKET 75
5.5 TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS 76
FIGURE 28 REVENUE SHIFT & NEW POCKETS FOR DRUG DISCOVERY SERVICE PROVIDERS 76
5.6 VALUE CHAIN ANALYSIS 76
FIGURE 29 VALUE CHAIN ANALYSIS OF DRUG DISCOVERY SERVICES MARKET: 
HIT-TO-LEAD IDENTIFICATION AND LEAD OPTIMIZATION PHASES ADD MAXIMUM VALUE 77
5.7 ECOSYSTEM ANALYSIS 77
FIGURE 30 ECOSYSTEM ANALYSIS: DRUG DISCOVERY SERVICES MARKET 78
TABLE 6 SUPPLY CHAIN ECOSYSTEM 78
5.8 TECHNOLOGY ANALYSIS 79
5.9 REGULATORY ANALYSIS 81
TABLE 7 REGULATORY SCENARIO 81
 
5.10 PORTER’S FIVE FORCES ANALYSIS 83
TABLE 8 DRUG DISCOVERY SERVICES MARKET: PORTER’S FIVE FORCES ANALYSIS 83
5.10.1 THREAT OF NEW ENTRANTS 83
5.10.2 THREAT OF SUBSTITUTES 83
5.10.3 BARGAINING POWER OF BUYERS 83
5.10.4 BARGAINING POWER OF SUPPLIERS 84
5.10.5 DEGREE OF COMPETITION 84
6 DRUG DISCOVERY SERVICES MARKET, BY PROCESS 85
6.1 INTRODUCTION 86
TABLE 9 DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 
2019–2026 (USD MILLION) 86
6.2 TARGET SELECTION 86
6.2.1 INCREASING DEMAND FOR PERSONALIZED MEDICINE TO SUPPORT THE GROWTH OF THIS MARKET 86
TABLE 10 DRUG DISCOVERY SERVICES MARKET FOR TARGET SELECTION, BY REGION, 2019–2026 (USD MILLION) 87
TABLE 11 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR TARGET SELECTION, BY COUNTRY, 2019–2026 (USD MILLION) 87
TABLE 12 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR TARGET SELECTION, 
BY COUNTRY, 2019–2026 (USD MILLION) 88
TABLE 13 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR TARGET SELECTION, BY COUNTRY, 2019–2026 (USD MILLION) 88
TABLE 14 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR TARGET SELECTION, BY COUNTRY, 2019–2026 (USD MILLION) 88
6.3 TARGET VALIDATION 89
6.3.1 RISING NUMBER OF DRUG DISCOVERY RESEARCH ACTIVITIES TO SUPPORT MARKET GROWTH 89
TABLE 15 DRUG DISCOVERY SERVICES MARKET FOR TARGET VALIDATION, BY REGION, 2019–2026 (USD MILLION) 89
TABLE 16 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR TARGET VALIDATION, BY COUNTRY, 2019–2026 (USD MILLION) 90
TABLE 17 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR TARGET VALIDATION, 
BY COUNTRY, 2019–2026 (USD MILLION) 90
TABLE 18 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR TARGET VALIDATION, BY COUNTRY, 2019–2026 (USD MILLION) 90
TABLE 19 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR TARGET VALIDATION, BY COUNTRY, 2019–2026 (USD MILLION) 91
6.4 HIT-TO-LEAD IDENTIFICATION 91
6.4.1 HIT-TO-LEAD IDENTIFICATION IS THE LARGEST PROCESS SEGMENT IN THE MARKET 91
TABLE 20 DRUG DISCOVERY SERVICES MARKET FOR HIT-TO-LEAD IDENTIFICATION, 
BY REGION, 2019–2026 (USD MILLION) 92
TABLE 21 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR HIT-TO-LEAD IDENTIFICATION, BY COUNTRY, 2019–2026 (USD MILLION) 92
TABLE 22 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR HIT-TO-LEAD IDENTIFICATION, BY COUNTRY, 2019–2026 (USD MILLION) 92
TABLE 23 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR HIT-TO-LEAD IDENTIFICATION, BY COUNTRY, 2019–2026 (USD MILLION) 93
TABLE 24 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR HIT-TO-LEAD IDENTIFICATION, BY COUNTRY, 2019–2026 (USD MILLION) 93
6.5 LEAD OPTIMIZATION 93
6.5.1 LEAD OPTIMIZATION REQUIRES STATE-OF-THE-ART INFORMATICS SYSTEMS TO FACILITATE TRANSPARENT PRESENTATION AND ANALYSIS 93
TABLE 25 DRUG DISCOVERY SERVICES MARKET FOR LEAD OPTIMIZATION, BY REGION, 2019–2026 (USD MILLION) 94
TABLE 26 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR LEAD OPTIMIZATION, BY COUNTRY, 2019–2026 (USD MILLION) 94
TABLE 27 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR LEAD OPTIMIZATION, 
BY COUNTRY, 2019–2026 (USD MILLION) 95
TABLE 28 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR LEAD OPTIMIZATION, BY COUNTRY, 2019–2026 (USD MILLION) 95
TABLE 29 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR LEAD OPTIMIZATION, BY COUNTRY, 2019–2026 (USD MILLION) 95
6.6 CANDIDATE VALIDATION 96
6.6.1 FUTURE MANUFACTURING SUITABILITY, SCALE-UP, COMMERCIAL VIABILITY, AND COST-EFFECTIVENESS OF CANDIDATES HEAVILY IMPACT THE LONG-TERM SUCCESS OF DRUGS 96
TABLE 30 DRUG DISCOVERY SERVICES MARKET FOR CANDIDATE VALIDATION, 
BY REGION, 2019–2026 (USD MILLION) 96
TABLE 31 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR CANDIDATE VALIDATION, BY COUNTRY, 2019–2026 (USD MILLION) 97
TABLE 32 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR CANDIDATE VALIDATION, BY COUNTRY, 2019–2026 (USD MILLION) 97
TABLE 33 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR CANDIDATE VALIDATION, BY COUNTRY, 2019–2026 (USD MILLION) 97
TABLE 34 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR CANDIDATE VALIDATION, BY COUNTRY, 2019–2026 (USD MILLION) 98
7 DRUG DISCOVERY SERVICES MARKET, BY TYPE 99
7.1 INTRODUCTION 100
TABLE 35 DRUG DISCOVERY SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION) 100
7.2 CHEMISTRY SERVICES 100
7.2.1 GROWING CHEMICAL & BIOCHEMICAL TESTS AND WIDE APPLICATIONS OF CHEMISTRY IN DRUG DISCOVERY ARE MAJOR FACTORS DRIVING MARKET GROWTH 100
TABLE 36 CHEMISTRY SERVICES MARKET, BY REGION, 2019–2026 (USD MILLION) 101
TABLE 37 NORTH AMERICA: CHEMISTRY SERVICES MARKET, BY COUNTRY, 
2019–2026 (USD MILLION) 101
TABLE 38 EUROPE: CHEMISTRY SERVICES MARKET, BY COUNTRY, 
2019–2026 (USD MILLION) 101
TABLE 39 APAC: CHEMISTRY SERVICES MARKET, BY COUNTRY, 
2019–2026 (USD MILLION) 102
TABLE 40 LATIN AMERICA: CHEMISTRY SERVICES MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 102
7.3 BIOLOGY SERVICES 102
7.3.1 THE INTRODUCTION OF GENOMICS AND PROTEOMICS WILL ENHANCE MARKET GROWTH 102
TABLE 41 BIOLOGY SERVICES MARKET, BY REGION, 2019–2026 (USD MILLION) 103
TABLE 42 NORTH AMERICA: BIOLOGY SERVICES MARKET, BY COUNTRY, 
2019–2026 (USD MILLION) 103
TABLE 43 EUROPE: BIOLOGY SERVICES MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 104
TABLE 44 APAC: BIOLOGY SERVICES MARKET, BY COUNTRY, 
2019–2026 (USD MILLION) 104
TABLE 45 LATIN AMERICA: BIOLOGY SERVICES MARKET, BY COUNTRY, 
2019–2026 (USD MILLION) 104
8 DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE 105
8.1 INTRODUCTION 106
TABLE 46 DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 
2019–2026 (USD MILLION) 106
8.2 SMALL-MOLECULE DRUGS 106
8.2.1 INCREASING NUMBER OF START-UPS AND NEW ENTRANTS IN THE SMALL-MOLECULE DRUGS SEGMENT WILL DRIVE THE GROWTH OF THIS MARKET 106
TABLE 47 DRUG DISCOVERY SERVICES MARKET FOR SMALL-MOLECULE DRUGS, 
BY REGION, 2019–2026 (USD MILLION) 107
TABLE 48 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR SMALL-MOLECULE DRUGS, BY COUNTRY, 2019–2026 (USD MILLION) 107
TABLE 49 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR SMALL-MOLECULE DRUGS, BY COUNTRY, 2019–2026 (USD MILLION) 108
TABLE 50 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR SMALL-MOLECULE DRUGS, BY COUNTRY, 2019–2026 (USD MILLION) 108
TABLE 51 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR SMALL-MOLECULE DRUGS, BY COUNTRY, 2019–2026 (USD MILLION) 108
8.3 BIOLOGIC DRUGS 109
8.3.1 SAFETY AND MANUFACTURING CHALLENGES ASSOCIATED WITH BIOLOGICS DEVELOPMENT TO DRIVE ADOPTION OF OUTSOURCING SERVICES 109
TABLE 52 DRUG DISCOVERY SERVICES MARKET FOR BIOLOGIC DRUGS, BY REGION, 2019–2026 (USD MILLION) 110
TABLE 53 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR BIOLOGIC DRUGS, BY COUNTRY, 2019–2026 (USD MILLION) 110
TABLE 54 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR BIOLOGIC DRUGS,
BY COUNTRY, 2019–2026 (USD MILLION) 110
TABLE 55 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR BIOLOGIC DRUGS, BY COUNTRY, 2019–2026 (USD MILLION) 111
TABLE 56 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR BIOLOGIC DRUGS, BY COUNTRY, 2019–2026 (USD MILLION) 111
9 DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA 112
9.1 INTRODUCTION 113
TABLE 57 DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 
2019–2026 (USD MILLION) 113
9.2 ONCOLOGY 113
9.2.1 HIGH AND GROWING NUMBER OF RESEARCH STUDIES ON CANCER THERAPEUTICS TO SUPPORT MARKET GROWTH 113
FIGURE 31 INCIDENCE OF MAJOR TYPES OF CANCER CASES WORLDWIDE (2020) 114
TABLE 58 LIST OF FDA-APPROVED DRUGS FOR ONCOLOGY (2020) 114
TABLE 59 ONCOLOGY DRUG DISCOVERY SERVICES MARKET, BY REGION, 
2019–2026 (USD MILLION) 115
TABLE 60 ONCOLOGY DRUG DISCOVERY SERVICES MARKET, BY COUNTRY, 
2019–2026 (USD MILLION) 115
TABLE 61 EUROPE: ONCOLOGY DRUG DISCOVERY SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 116
TABLE 62 ASIA PACIFIC: ONCOLOGY DRUG DISCOVERY SERVICES MARKET, 
BY COUNTRY, 2019–2026 (USD MILLION) 116
TABLE 63 LATIN AMERICA: ONCOLOGY DRUG DISCOVERY SERVICES MARKET, 
BY COUNTRY, 2019–2026 (USD MILLION) 116
9.3 INFECTIOUS & IMMUNE SYSTEM DISEASES 117
9.3.1 EPIDEMIC OUTBREAKS NECESSITATE INCREASING DRUG DISCOVERY ACTIVITIES 117
TABLE 64 INFECTIOUS & IMMUNE SYSTEM DISEASE DRUG DISCOVERY SERVICES MARKET, BY REGION, 2019–2026 (USD MILLION) 118
TABLE 65 NORTH AMERICA: INFECTIOUS & IMMUNE SYSTEM DISEASE DRUG DISCOVERY SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 118
TABLE 66 EUROPE: INFECTIOUS & IMMUNE SYSTEM DISEASE DRUG DISCOVERY SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 118
TABLE 67 ASIA PACIFIC: INFECTIOUS & IMMUNE SYSTEM DISEASE DRUG DISCOVERY SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 119
TABLE 68 LATIN AMERICA: INFECTIOUS & IMMUNE SYSTEM DISEASE DRUG DISCOVERY SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 119
9.4 NEUROLOGY 119
9.4.1 THE INCREASING NUMBER OF PATIENTS SUFFERING FROM NEUROLOGICAL DISORDERS IS DRIVING MARKET GROWTH 119
TABLE 69 MEDICINES IN DEVELOPMENT FOR NEUROGENERATIVE DISEASES (2021) 120
TABLE 70 NEUROLOGY DRUG DISCOVERY SERVICES MARKET, BY REGION, 
2019–2026 (USD MILLION) 120
TABLE 71 NORTH AMERICA: NEUROLOGY DRUG DISCOVERY SERVICES MARKET, 
BY COUNTRY, 2019–2026 (USD MILLION) 121
TABLE 72 EUROPE: NEUROLOGY DRUG DISCOVERY SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 121
TABLE 73 ASIA PACIFIC: NEUROLOGY DRUG DISCOVERY SERVICES MARKET, 
BY COUNTRY, 2019–2026 (USD MILLION) 121
TABLE 74 LATIN AMERICA: NEUROLOGY DRUG DISCOVERY SERVICES MARKET, 
BY COUNTRY, 2019–2026 (USD MILLION) 122
9.5 DIGESTIVE SYSTEM DISEASES 122
9.5.1 LARGE POPULATION SEEKING EFFECTIVE REMEDIES FOR DIGESTIVE DISEASES IS EXPECTED TO DRIVE THE MARKET 122
TABLE 75 DIGESTIVE SYSTEM DISEASE DRUG DISCOVERY SERVICES MARKET, 
BY REGION, 2019–2026 (USD MILLION) 123
TABLE 76 NORTH AMERICA: DIGESTIVE SYSTEM DISEASE DRUG DISCOVERY SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 123
TABLE 77 EUROPE: DIGESTIVE SYSTEM DISEASE DRUG DISCOVERY SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 123
TABLE 78 ASIA PACIFIC: DIGESTIVE SYSTEM DISEASE DRUG DISCOVERY SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 124
TABLE 79 LATIN AMERICA: DIGESTIVE SYSTEM DISEASE DRUG DISCOVERY SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 124
9.6 CARDIOVASCULAR DISEASES 124
9.6.1 THE HIGH GLOBAL BURDEN OF CARDIOVASCULAR DISEASES HAS INCREASED THE FOCUS ON DEVELOPING EFFECTIVE DRUGS 124
TABLE 80 LIST OF PIPELINE DRUGS FOR CARDIOVASCULAR DISEASES (2020) 125
TABLE 81 CARDIOVASCULAR DISEASE DRUG DISCOVERY SERVICES MARKET,
BY REGION, 2019–2026 (USD MILLION) 125
TABLE 82 NORTH AMERICA: CARDIOVASCULAR DISEASE DRUG DISCOVERY SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 126
TABLE 83 EUROPE: CARDIOVASCULAR DISEASE DRUG DISCOVERY SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 126
TABLE 84 ASIA PACIFIC: CARDIOVASCULAR DISEASE DRUG DISCOVERY SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 126
TABLE 85 LATIN AMERICA: CARDIOVASCULAR DISEASE DRUG DISCOVERY SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 127
9.7 OTHER THERAPEUTIC AREAS 127
TABLE 86 DRUG DISCOVERY SERVICES MARKET FOR OTHER THERAPEUTIC AREAS, 
BY REGION, 2019–2026 (USD MILLION) 128
TABLE 87 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2019–2026 (USD MILLION) 128
TABLE 88 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2019–2026 (USD MILLION) 128
TABLE 89 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2019–2026 (USD MILLION) 129
TABLE 90 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2019–2026 (USD MILLION) 129
10 DRUG DISCOVERY SERVICES MARKET, BY END USER 130
10.1 INTRODUCTION 131
TABLE 91 DRUG DISCOVERY SERVICES MARKET, BY END USER, 
2019–2026 (USD MILLION) 131
10.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 131
FIGURE 32 PHRMA MEMBER COMPANY R&D EXPENDITURE, 2017–2020 (USD BILLION) 132
TABLE 92 DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2019–2026 (USD MILLION) 132
TABLE 93 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 
2019–2026 (USD MILLION) 133
TABLE 94 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2019–2026 (USD MILLION) 133
TABLE 95 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2019–2026 (USD MILLION) 133
TABLE 96 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 
2019–2026 (USD MILLION) 134
10.2.1 DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE 134
TABLE 97 DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2019–2026 (USD MILLION) 134
10.2.2 TIER 1 COMPANIES 134
10.2.2.1 High investing capacity is the major factor driving the growth of this segment 134
TABLE 98 TOP PHARMA COMPANIES BY 2020 REVENUE 135
TABLE 99 DRUG DISCOVERY SERVICES MARKET FOR TIER 1 COMPANIES, BY REGION, 2019–2026 (USD MILLION) 135
TABLE 100 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR
TIER 1 COMPANIES, BY COUNTRY, 2019–2026 (USD MILLION) 135
10.2.3 TIER 2 COMPANIES 136
10.2.3.1 Limited investment capacity is expected to restrain the growth of this segment 136
TABLE 101 DRUG DISCOVERY SERVICES MARKET FOR TIER 2 COMPANIES, BY REGION, 2019–2026 (USD MILLION) 136
TABLE 102 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR 
TIER 2 COMPANIES, BY COUNTRY, 2019–2026 (USD MILLION) 136
10.2.4 TIER 3 COMPANIES 136
10.2.4.1 Tier 3 companies are smaller and have fewer technical advantages 136
TABLE 103 DRUG DISCOVERY SERVICES MARKET FOR TIER 3 COMPANIES, BY REGION, 2019–2026 (USD MILLION) 137
TABLE 104 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR 
TIER 3 COMPANIES, BY COUNTRY, 2019–2026 (USD MILLION) 137
10.3 ACADEMIC INSTITUTES 137
10.3.1 COLLABORATION WITH MARKET PLAYERS TO PROVIDE MORE FLEXIBLE AND EFFICIENT PATHWAYS FOR CLINICAL DEVELOPMENT 137
TABLE 105 DRUG DISCOVERY SERVICES MARKET FOR ACADEMIC INSTITUTES,
BY REGION, 2019–2026 (USD MILLION) 138
TABLE 106 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2019–2026 (USD MILLION) 138
TABLE 107 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2019–2026 (USD MILLION) 139
TABLE 108 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2019–2026 (USD MILLION) 139
TABLE 109 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2019–2026 (USD MILLION) 139
10.4 OTHER END USERS 140
TABLE 110 DRUG DISCOVERY SERVICES MARKET FOR OTHER END USERS, 
BY REGION, 2019–2026 (USD MILLION) 140
TABLE 111 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR OTHER END USERS, BY COUNTRY, 2019–2026 (USD MILLION) 140
TABLE 112 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR OTHER END USERS, 
BY COUNTRY, 2019–2026 (USD MILLION) 141
TABLE 113 ASIA PACIFIC: DRUG DISCOVERY SERVICES MARKET FOR OTHER END USERS, BY COUNTRY, 2019–2026 (USD MILLION) 141
TABLE 114 LATIN AMERICA: DRUG DISCOVERY SERVICES MARKET FOR 
OTHER END USERS, BY COUNTRY, 2019–2026 (USD MILLION) 141
11 DRUG DISCOVERY SERVICES MARKET, BY REGION 142
11.1 INTRODUCTION 143
TABLE 115 DRUG DISCOVERY SERVICES MARKET, BY REGION,
2019–2026 (USD MILLION) 143
11.2 NORTH AMERICA 143
FIGURE 33 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET SNAPSHOT 144
TABLE 116 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 144
TABLE 117 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 2019–2026 (USD MILLION) 145
TABLE 118 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 
2019–2026 (USD MILLION) 145
TABLE 119 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 2019–2026 (USD MILLION) 145
TABLE 120 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2019–2026 (USD MILLION) 146
TABLE 121 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET, BY END USER, 2019–2026 (USD MILLION) 146
TABLE 122 NORTH AMERICA: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 
2019–2026 (USD MILLION) 146
11.2.1 US 147
11.2.1.1 Availability of advanced R&D infrastructure has driven the growth of the US market 147
FIGURE 34 US CONTINUES TO DOMINATE THE DISTRIBUTION OF R&D COMPANIES 
BY REGION (2019 VS. 2020) 147
TABLE 123 US: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 
2019–2026 (USD MILLION) 148
TABLE 124 US: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 
2019–2026 (USD MILLION) 148
TABLE 125 US: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 
2019–2026 (USD MILLION) 148
TABLE 126 US: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 
2019–2026 (USD MILLION) 149
TABLE 127 US: DRUG DISCOVERY SERVICES MARKET, BY END USER, 
2019–2026 (USD MILLION) 149
TABLE 128 US: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2019–2026 (USD MILLION) 149
11.2.2 CANADA 150
11.2.2.1 Preference of pharmaceutical companies to conduct clinical trials in Canada to support market growth 150
TABLE 129 CANADA: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 
2019–2026 (USD MILLION) 151
TABLE 130 CANADA: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 
2019–2026 (USD MILLION) 151
TABLE 131 CANADA: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 
2019–2026 (USD MILLION) 151
TABLE 132 CANADA: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2019–2026 (USD MILLION) 152
TABLE 133 CANADA: DRUG DISCOVERY SERVICES MARKET, BY END USER, 
2019–2026 (USD MILLION) 152
TABLE 134 CANADA: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2019–2026 (USD MILLION) 152
11.3 EUROPE 153
TABLE 135 EUROPE: DRUG DISCOVERY SERVICES MARKET, BY COUNTRY, 
2019–2026 (USD MILLION) 153
TABLE 136 EUROPE: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 
2019–2026 (USD MILLION) 154
TABLE 137 EUROPE: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 
2019–2026 (USD MILLION) 154
TABLE 138 EUROPE: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 
2019–2026 (USD MILLION) 154
TABLE 139 EUROPE: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2019–2026 (USD MILLION) 155
TABLE 140 EUROPE: DRUG DISCOVERY SERVICES MARKET, BY END USER, 
2019–2026 (USD MILLION) 155
TABLE 141 EUROPE: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2019–2026 (USD MILLION) 155
11.3.1 GERMANY 156
11.3.1.1 Government support and flexible labor laws are driving the growth of the German drug discovery services market 156
TABLE 142 GERMANY: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 
2019–2026 (USD MILLION) 156
TABLE 143 GERMANY: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 
2019–2026 (USD MILLION) 156
TABLE 144 GERMANY: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 
2019–2026 (USD MILLION) 157
TABLE 145 GERMANY: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2019–2026 (USD MILLION) 157
TABLE 146 GERMANY: DRUG DISCOVERY SERVICES MARKET, BY END USER, 
2019–2026 (USD MILLION) 157
11.3.2 UK 158
11.3.2.1 Collaborations between the government and private stakeholders to support market growth 158
TABLE 147 UK: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 
2019–2026 (USD MILLION) 158
TABLE 148 UK: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 
2019–2026 (USD MILLION) 158
TABLE 149 UK: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 
2019–2026 (USD MILLION) 159
TABLE 150 UK: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 
2019–2026 (USD MILLION) 159
TABLE 151 UK: DRUG DISCOVERY SERVICES MARKET, BY END USER, 
2019–2026 (USD MILLION) 159
11.3.3 FRANCE 160
11.3.3.1 The high number of oncology research projects in France to drive market growth 160
TABLE 152 FRANCE: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 
2019–2026 (USD MILLION) 160
TABLE 153 FRANCE: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 
2019–2026 (USD MILLION) 161
TABLE 154 FRANCE: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 
2019–2026 (USD MILLION) 161
TABLE 155 FRANCE: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2019–2026 (USD MILLION) 161
TABLE 156 FRANCE: DRUG DISCOVERY SERVICES MARKET, BY END USER, 
2019–2026 (USD MILLION) 162
11.3.4 ITALY 162
11.3.4.1 High number of clinical trials and the low drug approval time are the major factors driving market growth 162
TABLE 157 NUMBER OF CLINICAL TRIALS STARTED IN ITALY, BY COMPANY (JANUARY 2021) 163
TABLE 158 ITALY: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 
2019–2026 (USD MILLION) 163
TABLE 159 ITALY: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 
2019–2026 (USD MILLION) 163
TABLE 160 ITALY: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE,
 2019–2026 (USD MILLION) 164
TABLE 161 ITALY: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA,
 2019–2026 (USD MILLION) 164
TABLE 162 ITALY: DRUG DISCOVERY SERVICES MARKET, BY END USER, 
2019–2026 (USD MILLION) 164
11.3.5 SPAIN 165
11.3.5.1 Short study start-up times and rising R&D expenditure to boost the growth of the Spanish market 165
TABLE 163 SPAIN: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 
2019–2026 (USD MILLION) 165
TABLE 164 SPAIN: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 
2019–2026 (USD MILLION) 166
TABLE 165 SPAIN: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 
2019–2026 (USD MILLION) 166
TABLE 166 SPAIN: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2019–2026 (USD MILLION) 166
TABLE 167 SPAIN: DRUG DISCOVERY SERVICES MARKET, BY END USER, 
2019–2026 (USD MILLION) 167
11.3.6 REST OF EUROPE 167
TABLE 168 ROE: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 
2019–2026 (USD MILLION) 168
TABLE 169 ROE: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 
2019–2026 (USD MILLION) 168
TABLE 170 ROE: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 
2019–2026 (USD MILLION) 168
TABLE 171 ROE: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 
2019–2026 (USD MILLION) 169
TABLE 172 ROE: DRUG DISCOVERY SERVICES MARKET, BY END USER, 
2019–2026 (USD MILLION) 169
11.4 ASIA PACIFIC 169
FIGURE 35 APAC: DRUG DISCOVERY SERVICES MARKET SNAPSHOT 170
TABLE 173 APAC: DRUG DISCOVERY SERVICES MARKET, BY COUNTRY, 
2019–2026 (USD MILLION) 171
TABLE 174 APAC: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 
2019–2026 (USD MILLION) 171
TABLE 175 APAC: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 
2019–2026 (USD MILLION) 171
TABLE 176 APAC: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 
2019–2026 (USD MILLION) 172
TABLE 177 APAC: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 
2019–2026 (USD MILLION) 172
TABLE 178 APAC: DRUG DISCOVERY SERVICES MARKET, BY END USER, 
2019–2026 (USD MILLION) 172
TABLE 179 APAC: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2019–2026 (USD MILLION) 173
11.4.1 CHINA 173
11.4.1.1 China dominates the Asia Pacific market due to a robust pharmaceutical industry and the presence of prominent CROs 173
TABLE 180 CHINA: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 
2019–2026 (USD MILLION) 174
TABLE 181 CHINA: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 
2019–2026 (USD MILLION) 174
TABLE 182 CHINA: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 
2019–2026 (USD MILLION) 174
TABLE 183 CHINA: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2019–2026 (USD MILLION) 175
TABLE 184 CHINA: DRUG DISCOVERY SERVICES MARKET, BY END USER, 
2019–2026 (USD MILLION) 175
11.4.2 JAPAN 175
11.4.2.1 Government initiatives for drug innovation to support market growth in Japan 175
TABLE 185 JAPAN: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 
2019–2026 (USD MILLION) 176
TABLE 186 JAPAN: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 
2019–2026 (USD MILLION) 176
TABLE 187 JAPAN: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 
2019–2026 (USD MILLION) 177
TABLE 188 JAPAN: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2019–2026 (USD MILLION) 177
TABLE 189 JAPAN: DRUG DISCOVERY SERVICES MARKET, BY END USER, 
2019–2026 (USD MILLION) 177
11.4.3 INDIA 178
11.4.3.1 Low-cost services and availability of skilled workforce and strong government support to drive market growth in India 178
TABLE 190 INDIA: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 
2019–2026 (USD MILLION) 178
TABLE 191 INDIA: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 
2019–2026 (USD MILLION) 179
TABLE 192 INDIA: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 
2019–2026 (USD MILLION) 179
TABLE 193 INDIA: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 
2019–2026 (USD MILLION) 179
TABLE 194 INDIA: DRUG DISCOVERY SERVICES MARKET, BY END USER,
2019–2026 (USD MILLION) 180
11.4.4 SOUTH KOREA 180
11.4.4.1 Government initiatives and growing R&D activities for drug development to drive market growth 180
TABLE 195 SOUTH KOREA: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 
2019–2026 (USD MILLION) 181
TABLE 196 SOUTH KOREA: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 
2019–2026 (USD MILLION) 181
TABLE 197 SOUTH KOREA: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE,
2019–2026 (USD MILLION) 181
TABLE 198 SOUTH KOREA: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2019–2026 (USD MILLION) 182
TABLE 199 SOUTH KOREA: DRUG DISCOVERY SERVICES MARKET, BY END USER, 
2019–2026 (USD MILLION) 182
11.4.5 REST OF ASIA PACIFIC 182
TABLE 200 ROAPAC: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 
2019–2026 (USD MILLION) 183
TABLE 201 ROAPAC: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 
2019–2026 (USD MILLION) 183
TABLE 202 ROAPAC: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 
2019–2026 (USD MILLION) 183
TABLE 203 ROAPAC: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2019–2026 (USD MILLION) 184
TABLE 204 ROAPAC: DRUG DISCOVERY SERVICES MARKET, BY END USER, 
2019–2026 (USD MILLION) 184
11.5 LATIN AMERICA 184
TABLE 205 LATAM: DRUG DISCOVERY SERVICES MARKET, BY COUNTRY, 
2019–2026 (USD MILLION) 185
TABLE 206 LATAM: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 
2019–2026 (USD MILLION) 185
TABLE 207 LATAM: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 
2019–2026 (USD MILLION) 185
TABLE 208 LATAM: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 
2019–2026 (USD MILLION) 186
TABLE 209 LATAM: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2019–2026 (USD MILLION) 186
TABLE 210 LATAM: DRUG DISCOVERY SERVICES MARKET, BY END USER, 
2019–2026 (USD MILLION) 186
TABLE 211 LATAM: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2019–2026 (USD MILLION) 187
11.5.1 BRAZIL 187
11.5.1.1 The presence of a large pool of treatment-naïve patients and short approval timeline is expected to drive market growth in this region 187
TABLE 212 BRAZIL: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 
2019–2026 (USD MILLION) 187
TABLE 213 BRAZIL: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 
2019–2026 (USD MILLION) 188
TABLE 214 BRAZIL: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 
2019–2026 (USD MILLION) 188
TABLE 215 BRAZIL: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2019–2026 (USD MILLION) 188
TABLE 216 BRAZIL: DRUG DISCOVERY SERVICES MARKET, BY END USER, 
2019–2026 (USD MILLION) 189
11.5.2 REST OF LATIN AMERICA 189
TABLE 217 ROLATAM: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 
2019–2026 (USD MILLION) 189
TABLE 218 ROLATAM: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 
2019–2026 (USD MILLION) 190
TABLE 219 ROLATAM: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 
2019–2026 (USD MILLION) 190
TABLE 220 ROLATAM: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 2019–2026 (USD MILLION) 190
TABLE 221 ROLATAM: DRUG DISCOVERY SERVICES MARKET, BY END USER, 
2019–2026 (USD MILLION) 191
11.6 MIDDLE EAST & AFRICA 191
11.6.1 GROWING PHARMACEUTICAL INDUSTRY TO DRIVE MARKET GROWTH IN THE MIDDLE EAST AND AFRICA 191
TABLE 222 MEA: DRUG DISCOVERY SERVICES MARKET, BY PROCESS, 
2019–2026 (USD MILLION) 192
TABLE 223 MEA: DRUG DISCOVERY SERVICES MARKET, BY TYPE, 
2019–2026 (USD MILLION) 192
TABLE 224 MEA: DRUG DISCOVERY SERVICES MARKET, BY DRUG TYPE, 
2019–2026 (USD MILLION) 192
TABLE 225 MEA: DRUG DISCOVERY SERVICES MARKET, BY THERAPEUTIC AREA, 
2019–2026 (USD MILLION) 193
TABLE 226 MEA: DRUG DISCOVERY SERVICES MARKET, BY END USER, 
2019–2026 (USD MILLION) 193
TABLE 227 MEA: DRUG DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY TYPE, 2019–2026 (USD MILLION) 193
 
12 COMPETITIVE LANDSCAPE 194
12.1 OVERVIEW 194
12.2 KEY PLAYERS STRATEGIES/RIGHT TO WIN 195
FIGURE 36 KEY PLAYERS STRATEGIES IN THE DRUG DISCOVERY SERVICES MARKET, 2019–2021 195
12.3 MARKET SHARE ANALYSIS 196
FIGURE 37 DRUG DISCOVERY SERVICES MARKET: MARKET SHARE ANALYSIS, 
BY KEY PLAYER, 2020 196
TABLE 228 DRUG DISCOVERY SERVICES MARKET: DEGREE OF COMPETITION 196
12.4 REVENUE SHARE ANALYSIS OF THE TOP MARKET PLAYERS 197
FIGURE 38 REVENUE SHARE ANALYSIS OF TOP PLAYERS IN THE DRUG DISCOVERY MARKET, 2018–2020 197
12.5 COMPANY EVALUATION QUADRANT 198
12.5.1 STARS 198
12.5.2 EMERGING LEADERS 198
12.5.3 PERVASIVE PLAYERS 198
12.5.4 PARTICIPANTS 198
FIGURE 39 DRUG DISCOVERY SERVICES MARKET: COMPANY EVALUATION 
QUADRANT, 2020 199
12.6 COMPANY EVALUATION QUADRANT: START-UPS/SMES 200
12.6.1 PROGRESSIVE COMPANIES 200
12.6.2 STARTING BLOCKS 200
12.6.3 RESPONSIVE COMPANIES 200
12.6.4 DYNAMIC COMPANIES 200
FIGURE 40 DRUG DISCOVERY SERVICES MARKET: COMPANY EVALUATION 
QUADRANT FOR START-UPS/SMES, 2020 201
12.7 COMPANY SERVICE FOOTPRINT 202
TABLE 229 PRODUCT PORTFOLIO ANALYSIS: DRUG DISCOVERY 
SERVICES MARKET (2020) 202
12.8 COMPANY GEOGRAPHIC FOOTPRINT 203
TABLE 230 GEOGRAPHIC REVENUE MIX: DRUG DISCOVERY SERVICES MARKET (2020) 203
12.9 COMPETITIVE SCENARIO 204
12.9.1 SERVICE LAUNCHES 204
TABLE 231 SERVICE LAUNCHES 204
12.9.2 DEALS 205
TABLE 232 DEALS 205
12.9.3 EXPANSIONS 206
TABLE 233 EXPANSIONS 206
 
13 COMPANY PROFILES 207
(Business Overview, Services offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
13.1 KEY PLAYERS 207
13.1.1 LABORATORY CORPORATION OF AMERICA HOLDINGS 207
TABLE 234 LABORATORY CORPORATION OF AMERICA HOLDINGS: BUSINESS OVERVIEW 207
FIGURE 41 LABORATORY CORPORATION OF AMERICA HOLDINGS: 
COMPANY SNAPSHOT (2020) 208
13.1.2 CHARLES RIVER LABORATORIES INTERNATIONAL, INC. 211
TABLE 235 CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: BUSINESS OVERVIEW 211
FIGURE 42 CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: 
COMPANY SNAPSHOT (2020) 212
13.1.3 WUXI APPTEC 218
TABLE 236 WUXI APPTEC: BUSINESS OVERVIEW 218
FIGURE 43 WUXI APPTEC: COMPANY SNAPSHOT (2020) 219
13.1.4 THERMO FISHER SCIENTIFIC 223
TABLE 237 THERMO FISHER SCIENTIFIC: BUSINESS OVERVIEW 223
FIGURE 44 THERMO FISHER SCIENTIFIC INC: COMPANY SNAPSHOT (2020) 224
13.1.5 PHARMARON BEIJING CO., LTD. 227
TABLE 238 PHARMARON BEIJING CO., LTD.: BUSINESS OVERVIEW 227
FIGURE 45 PHARMARON BEIJING CO., LTD.: COMPANY SNAPSHOT (2020) 228
13.1.6 EVOTEC SE 232
TABLE 239 EVOTEC SE: BUSINESS OVERVIEW 232
FIGURE 46 EVOTEC SE: COMPANY SNAPSHOT (2020) 233
13.1.7 EUROFINS SCIENTIFIC SE 240
TABLE 240 EUROFINS SCIENTIFIC SE: BUSINESS OVERVIEW 240
FIGURE 47 EUROFINS SCIENTIFIC SE: COMPANY SNAPSHOT (2020) 241
13.1.8 PHARMACEUTICAL PRODUCT DEVELOPMENT, INC. 248
TABLE 241 PHARMACEUTICAL PRODUCT DEVELOPMENT, INC.: BUSINESS OVERVIEW 248
FIGURE 48 PHARMACEUTICAL PRODUCT DEVELOPMENT, INC.: 
COMPANY SNAPSHOT (2020) 249
13.1.9 PIRAMAL ENTERPRISES LIMITED 250
TABLE 242 PIRAMAL ENTERPRISES LIMITED: BUSINESS OVERVIEW 250
FIGURE 49 PIRAMAL ENTERPRISES LIMITED: COMPANY SNAPSHOT (2020) 251
13.1.10 SYNGENE INTERNATIONAL LIMITED 253
TABLE 243 SYNGENE INTERNATIONAL LIMITED: BUSINESS OVERVIEW 253
FIGURE 50 SYNGENE INTERNATIONAL LIMITED: COMPANY SNAPSHOT (2020) 254
13.1.11 CURIA GLOBAL INC. 257
TABLE 244 CURIA GLOBAL INC.: BUSINESS OVERVIEW 257
13.1.12 GENSCRIPT BIOTECH CORPORATION 260
TABLE 245 GENSCRIPT BIOTECH CORPORATION: BUSINESS OVERVIEW 260
FIGURE 51 GENSCRIPT BIOTECH CORPORATION: COMPANY SNAPSHOT (2020) 261
13.1.13 JUBILANT PHARMOVA LIMITED 263
TABLE 246 JUBILANT PHARMOVA LIMITED: BUSINESS OVERVIEW 263
FIGURE 52 JUBILANT PHARMOVA LIMITED: COMPANY SNAPSHOT (2020) 264
13.1.14 FRONTAGE HOLDINGS CORPORATION 267
TABLE 247 FRONTAGE HOLDINGS CORPORATION: BUSINESS OVERVIEW 267
FIGURE 53 FRONTAGE HOLDINGS CORPORATION: COMPANY SNAPSHOT (2020) 268
13.1.15 SHANGHAI MEDICILON INC. 271
TABLE 248 SHANGHAI MEDICILON INC.: BUSINESS OVERVIEW 271
13.1.16 DR. REDDY’S LABORATORIES LTD. (AURIGENE DISCOVERY TECHNOLOGIES) 273
TABLE 249 DR. REDDY’S LABORATORIES LTD.: BUSINESS OVERVIEW 273
FIGURE 54 DR. REDDY’S LABORATORIES LTD.: COMPANY SNAPSHOT (2020) 274
13.2 OTHER COMPANIES 276
13.2.1 SELVITA S.A. (FORMERLY SELVITA CRO S.A.) 276
13.2.2 VIVA BIOTECH (SHANGHAI) LTD. 277
13.2.3 TCG LIFESCIENCES PVT LTD. 278
13.2.4 SHANGHAI CHEMPARTNER CO., LTD. 279
13.2.5 DOMAINEX LTD. 280
13.2.6 NUVISAN PHARMA HOLDING GMBH 281
13.2.7 DALTON PHARMA SERVICES 282
13.2.8 ARAGEN LIFE SCIENCES PVT. LTD. (FORMERLY GVK BIOSCIENCES PVT. LTD.) 283
13.2.9 PROMEGA CORPORATION 284
*Details on Business Overview, Services offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
14 APPENDIX 285
14.1 DISCUSSION GUIDE 285
14.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 289
14.3 AVAILABLE CUSTOMIZATIONS 291
14.4 RELATED REPORTS 291
14.5 AUTHOR DETAILS 292

 

　

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野（薬学的薬物）の最新刊レポート

MarketsandMarkets社のその他分野での最新刊レポート

本レポートと同じKEY WORD（oncology）の最新刊レポート


よくあるご質問


MarketsandMarkets社はどのような調査会社ですか?


マーケッツアンドマーケッツ（MarketsandMarkets）は通信、半導体、医療機器、エネルギーなど、幅広い市場に関する調査レポートを出版しています。また広範な市場を対象としたカスタム調査も行って... もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
お客様よりデータリソース社へ（通常は円払い）の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。



詳細検索

このレポートへのお問合せ

お問合せはこちらから

03-3582-2531

電話お問合せもお気軽に

 

2024/11/15　10:26

157.84 円

166.62 円

202.61 円

ページTOPに戻る

株式会社 データリソース　Data Resources, Inc.
東京都港区赤坂1-14-5　アークヒルズエグゼクティブタワー N313

電話：03-3582-2531
FAX：03-3582-2861
Eメール：office@dri.co.jp

FAQ サイトマップ プライバシーポリシー お問合せ

関連会社:
株式会社ユーディーアール

COPYRIGHT(C) 2011-2023　DATA RESOURCES, Inc. ALL RIGHTS RESERVED.